Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Clinical trial NCT07211958 · RECRUITING

Trial details

NCT number: NCT07211958
Sponsor: Syndax Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemias

Start date: 2025-11-25
Primary completion: 2029-06-01
Enrollment: 468

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.